Anti-Hu CD3 Alexa Fluor® 488

Anti-Hu CD3 Alexa Fluor® 488
Regulatory status
RUO
Antigen
CD3
Clone
OKT3
Format
Alexa Fluor® 488
Reactivity
Human
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
A4-631-T100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG2a
Specificity
The mouse monoclonal antibody OKT3 recognizes an extracellular epitope on CD3 antigen of the TCR/CD3 complex on mature human T cells. This antibody, also known as Orthoclone OKT3 or Muromonab-CD3, has been extensively used as a drug for therapy of acute, glucocorticoid resistant rejection of allogenic renal, heart and liver transplants. It has also been investigated for use in treating T-cell acute lymphoblastic leukemia.
Workshop
HLDA VI: WS Code T6T-R3
Application
FC (QC tested)
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human
Immunogen
Commercially sensitive information
Other names
CD3E, T3E, TCRE
Preparation
The purified antibody is conjugated with Alexa Fluor® 488 under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchsing a license to this product for purposes orther than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.
A4-631 FC
Flow cytometry analysis (surface staining) of peripheral blood leukocytes using anti-CD3 (OKT3) Alexa Fluor® 488.

General references:

Huang Y, Wange RL: T cell receptor signaling: beyond complex complexes. J Biol Chem. 2004 Jul 9;279(28):28827-30.
PubMed
Alarcón B, Swamy M, van Santen HM, Schamel WW: T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity. EMBO Rep. 2006 May;7(5):490-5.
PubMed
Kuhns MS, Davis MM, Garcia KC: Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006 Feb;24(2):133-9.
PubMed

Product specific references:

Gordon PR, Leimig T, Mueller I, Babarin-Dorner A, Holladay MA, Houston J, Kerst G, Geiger T, Handgretinger R: A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 2002 Jul;30(2):69-74.
PubMed
Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L: Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull. 2010 Jan;33(1):40-6.
PubMed
Undale AH, van den Elsen PJ, Celis E: Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol. 2004 Oct;16(10):1523-33.
PubMed
Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, Schwarz EC, Hoth M: T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14418-23.
PubMed
Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV, Badley AD. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol. 2005 Aug;79(15):9821-30.
PubMed
Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T: Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003 Feb 15;101(4):1630-6.
PubMed
Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, Klingebiel T: OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol. 2000 Nov;111(2):668-73.
PubMed
Smith SL: Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996 Sep;6(3):109-19; quiz 120-1.
PubMed
Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S: MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 1996 Sep 15;56(18):4205-12.
PubMed
Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS: Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003 Oct;17(10):1973-80.
PubMed
Variant
100 tests
A4-631-T100
In stock
Variant
0.1 mg
11-261-C100
In stock